Vertex Pharmaceuticals (VRTX) opened 2026 with Q1 results that build on a solid recent run, following Q4 2025 revenue of US$3.2 billion and basic EPS of US$4.69, supported by trailing 12 month revenue of US$12.0 billion and basic EPS of US$15.46. Over the past few quarters, the company has seen revenue move from US$2.8 billion in Q1 2025 to US$3.2 billion in Q4 2025, while basic EPS shifted from US$2.52 to US$4.69. This points to a business where profitability trends are front and center for how you think about margins and future durability.

See our full analysis for Vertex Pharmaceuticals.

With the headline numbers on the table, the next step is to see how these results line up with the widely followed narratives about Vertex, and where the latest margins and growth profile push back against those expectations.

Profitability Back After Five Tough Years

• Trailing 12 month net income sits at about US$4.0b, with Basic EPS of US$15.46, compared with a five year stretch where earnings declined on average by 6.3% a year and were loss making as recently as 2024.
• Bulls argue that the move from losses in 2024 to US$3.95b of trailing 12 month profit heavily supports their view that earnings can compound from this new base, yet the past five year earnings decline keeps a check on that optimism.
  • On the bullish side, the consensus forecast of roughly 13.6% annual earnings growth and about 9.7% annual revenue growth is being anchored to the current US$12.0b revenue and positive EPS run rate.
  • Set against that, critics point to the earlier loss making trailing 12 month periods in 2024 as a reminder that the recent profit profile is still relatively young when thinking about long term durability.

Over the last year, bulls say Vertex has flipped the script on profitability, and they see that US$3.95b profit run rate as the base for a much larger earnings story, while skeptics keep pointing back to the prior five year decline to argue the current phase still needs to prove itself before it can be treated as a new normal. 🐂 Vertex Pharmaceuticals Bull Case

DCF Value And P/E Send Mixed Signals

• The stock trades at US$424.36 while the provided DCF fair value is US$764.83 and analyst targets cluster around US$549.50, and the current P/E of 27.3x sits below a 40x peer average but above the broader US biotechs industry at 17.2x.
• Bears highlight that paying a 27.3x P/E that is richer than the wider biotechs industry could be demanding if forecast revenue growth around 9.7% a year stays below the wider US market, even though the DCF value and price targets suggest upside.
  • On one side, the gap between US$424.36 and the US$764.83 DCF fair value, together with the US$549.50 target, lines up with the view that current pricing assumes a more cautious path than models and targets imply.
  • On the other, the higher multiple than the broader industry and the history of 6.3% annual earnings decline give bears numbers to support the idea that Vertex may already be priced above slower growing biotech peers.

Skeptics warn that paying a premium P/E to the wider biotech industry, while growth forecasts sit below the broader US market, puts more pressure on the company to live up to the DCF and target price optimism baked into those higher valuation marks. 🐻 Vertex Pharmaceuticals Bear Case

Revenue Trend Supports But Doesn’t Match Growth Narratives

• Quarterly revenue has moved from US$2.77b in Q1 2025 to US$3.19b in Q4 2025, and trailing 12 month revenue has gone from about US$10.6b in Q3 2024 to US$12.0b in Q4 2025, while forward looking models point to roughly 9.7% annual revenue growth that is below the 11.2% US market figure cited.
• The balanced narrative around Vertex leans on a 10% annual revenue growth assumption and margin expansion to 37.0%, yet the current trailing 12 month revenue base and the slower than market growth forecast mean investors have to weigh pipeline optimism against that measured top line profile.
  • Supporters of the consensus view point out that products like ALYFTREK, CASGEVY and JOURNAVX are already contributing to the US$12.0b revenue base, which underpins expectations for mid single digit to low double digit annual growth.
  • At the same time, the forecast that both revenue and earnings growth will sit below broad US market averages and the prior five year earnings decline keep the focus on execution rather than assuming that pipeline momentum automatically translates to faster growth.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Vertex Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Given the mix of cautious and optimistic views so far, it helps to see the numbers for yourself rather than rely on headlines. Take a closer look at the 4 key rewards.

See What Else Is Out There

For all the optimism around profitability returning, Vertex still carries a history of five year earnings decline and forecasts that sit below broad US market growth.

If you want ideas where growth expectations and valuations may line up more cleanly, check out the 52 high quality undervalued stocks to find stocks priced with more modest assumptions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.